AI Article Synopsis
- The investigation focused on how Tweed edgewise treatment impacts horizontal growth of the mandible while maintaining vertical control in patients.
- The study involved 36 patients with extracted premolars, comparing their treatment results with untreated controls using cephalometric analysis.
- Results indicated that while the treatment prevented downward rotation of the mandible, it did not promote forward rotation, although overall growth patterns were favorable when compared to maxillary changes.
Article Abstract
Introduction: The purpose of this investigation was to examine the effect of Tweed edgewise treatment on the expression of mandibular growth in the horizontal direction through maintenance of vertical control.
Methods: We studied 36 patients who had 4 premolars extracted during treatment. Pretreatment, posttreatment, and postretention records of these patients were matched by age (± 6 months), sex, malocclusion, and treatment interval (± 6 months) to untreated controls from the Bolton-Brush Growth Study Center, Cleveland, Ohio. The cephalograms of the 2 samples were traced, digitized, and analyzed by descriptive cephalometric analysis and detailed regional superimposition.
Results: Tweed edgewise treatment can prevent clockwise rotation but was not observed to enhance the normal forward rotation of the mandible. The mandible did not rotate forward in the treated patients who underwent a greater chin advancement.
Conclusions: The pattern of skeletal change was favorable both during treatment and in later years. A feature of this effect was an improved pattern of mandibular growth displacement, when mandibular change was compared with maxillary change.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ajodo.2013.07.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Worsening of Heart Failure in Outpatients With Transthyretin Amyloidosis and Cardiomyopathy in the APOLLO-B Trial.
J Am Coll Cardiol
December 2024
Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts, USA. Electronic address:
Background: Outpatient worsening heart failure (HF), defined by initiation or intensification of diuretics, is adversely prognostic for patients with either reduced or preserved ejection fraction.
Objectives: This study sought to investigate the prognostic value of outpatient worsening HF in transthyretin amyloidosis with cardiomyopathy and the effect of patisiran treatment.
Methods: Post hoc analyses of the APOLLO-B trial (NCT03997383) evaluated the associations between outpatient worsening HF (defined by oral diuretic initiation or intensification), measures of disease progression, and a composite endpoint of all-cause mortality and cardiovascular (CV) events.
Recommendations for mitochondria transfer and transplantation nomenclature and characterization.
Nat Metab
January 2025
Centre for Orthopaedic Research, Medical School of the University of Western Australia, Nedlands, Western Australia, Australia.
Intercellular mitochondria transfer is an evolutionarily conserved process in which one cell delivers some of their mitochondria to another cell in the absence of cell division. This process has diverse functions depending on the cell types involved and physiological or disease context. Although mitochondria transfer was first shown to provide metabolic support to acceptor cells, recent studies have revealed diverse functions of mitochondria transfer, including, but not limited to, the maintenance of mitochondria quality of the donor cell and the regulation of tissue homeostasis and remodelling.
View Article and Find Full Text PDFFinerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial.
Lancet Diabetes Endocrinol
January 2025
British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK. Electronic address:
Background: Data on the effect of mineralocorticoid receptor antagonist therapy on HbA levels and new-onset diabetes are conflicting. We aimed to examine the effect of oral finerenone, compared with placebo, on incident diabetes in the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure (FINEARTS-HF) trial.
Methods: In this randomised, double-blind, placebo-controlled trial, 6001 participants with heart failure with New York Heart Association functional class II-IV, left ventricular ejection fraction 40% or higher, evidence of structural heart disease, and elevated N-terminal pro-B-type natriuretic peptide levels were randomly assigned to finerenone or placebo, administered orally.
Initial Decline in Glomerular Filtration Rate With Finerenone in HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HF.
J Am Coll Cardiol
January 2025
British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom. Electronic address:
Background: An initial decline in estimated glomerular filtration rate (eGFR) often leads to reluctance to continue life-saving therapies in patients with heart failure (HF).
Objectives: The goal of this study was to describe the association between initial decline in eGFR and subsequent clinical outcomes in patients randomized to placebo or finerenone.
Methods: In this prespecified analysis of FINEARTS-HF (Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure), we examined the association between initial decline in eGFR (≥15%) from randomization to 1 month and subsequent outcomes in patients assigned to finerenone or placebo.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!